Glycine N-methyltransferase affects the metabolism of aflatoxin B{sub 1} and blocks its carcinogenic effect
Previously, we reported that glycine N-methyltransferase (GNMT) knockout mice develop chronic hepatitis and hepatocellular carcinoma (HCC) spontaneously. For this study we used a phosphoenolpyruvate carboxykinase promoter to establish a GNMT transgenic (TG) mouse model. Animals were intraperitoneally inoculated with aflatoxin B{sub 1} (AFB{sub 1}) and monitored for 11 months, during which neither male nor female GNMT-TG mice developed HCC. In contrast, 4 of 6 (67%) male wild-type mice developed HCC. Immunofluorescent antibody test showed that GNMT was translocated into nuclei after AFB{sub 1} treatment. Competitive enzyme immunoassays indicated that after AFB{sub 1} treatment, the AFB{sub 1}-DNA adducts formed in stable clones expressing GNMT reduced 51.4% compared to the vector control clones. Experiments using recombinant adenoviruses carrying GNMT cDNA (Ad-GNMT) further demonstrated that the GNMT-related inhibition of AFB{sub 1}-DNA adducts formation is dose-dependent. HPLC analysis of the metabolites of AFB{sub 1} in the cultural supernatants of cells exposed to AFB{sub 1} showed that the AFM{sub 1} level in the GNMT group was significantly higher than the control group, indicating the presence of GNMT can enhance the detoxification pathway of AFB{sub 1}. Cytotoxicity assay showed that the GNMT group had higher survival rate than the control group after they were treated with AFB{sub 1}. Automated docking experiments showed that AFB{sub 1} binds to the S-adenosylmethionine binding domain of GNMT. Affinity sensor assay demonstrated that the dissociation constant for GNMT-AFB{sub 1} interaction is 44.9 {mu}M. Therefore, GNMT is a tumor suppressor for HCC and it exerts protective effects in hepatocytes via direct interaction with AFB{sub 1}, resulting in reduced AFB{sub 1}-DNA adducts formation and cell death.